Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Trial of Amivita in Amyotrophic Lateral Sclerosis
The primary objectives of this study are to determine the safety and efficacy of Amivita, a compound of amino acids and vitamines in patients with Amyotrophic lateral sclerosis (ALS)ALS.
- Trial name
- NCT03103815
- Testing
- Amivita
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wujin People's Hospital
Amyotrophic Lateral Sclerosis
Perception of Unpleasant Sensations During Study Procedures in ALS Patients
Diagnosis of Amyotrophic Lateral Sclerosis (ALS) is considered a traumatic life event for both the patient and their next-of-kin/carers, due to the lack of treatment.
- Trial name
- PESALS (NCT06325865)
- Testing
- Interview
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Istituto Auxologico Italiano
Amyotrophic Lateral Sclerosis
Accurate Test of Limb Isometric Strength (ATLIS) in ALS
A strength measurement device called Accurate Test of Limb Isometric Strength (ATLIS) was developed to precisely and conveniently measure static limb strength in patients with ALS.
- Trial name
- NCT02374606
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
Amyotrophic Lateral Sclerosis &Amp; Other Neuromuscular Disorders
Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by the degeneration of motor neurons leading to progressive paralysis and death within 3 to 5 years after diagnosis.
- Trial name
- PALS (NCT07091799)
- Testing
- P2X4 receptors in blood samples
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Amyotrophic Lateral Sclerosis Als
Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis
The goal of the study aims to evaluate the safety and tolerability of a single intrathecal injection of RJK002 in subjects with amyotrophic lateral sclerosis (ALS), and to determine the recommended Phase II dose (RP2D).
- Trial name
- NCT06493279
- Testing
- RJK002 Intrathecal injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- RJK Biopharma Ltd
Amyotrophic Lateral Sclerosis, ALS
Open Label Extension Study of AMX0035 in Patients With ALS
This extension study, in which all participants received active treatment (AMX0035), was designed to assess the longer-term safety and therapeutic potential of AMX0035 for participants who have completed the Main Study (AMX3500…
- Trial name
- CENTAUR-OLE (NCT03488524)
- Testing
- AMX0035
- Where
- 24 sites in United States
- Volunteers
- 90 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis
This is a randomized double blinded randomized 2:1 study. The duration of the study is 6 month. The safety and tolerability of high doses of biotin (300 mg/ day) will be compared to placebo in patients with amyotrophic lateral…
- Trial name
- NCT03427086
- Testing
- Biotin
- Where
- Lebanon
- Volunteers
- 12 people
- Sponsor
- American University of Beirut Medical Center
Amyotrophic Lateral Sclerosis
A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis
People with Amyotrophic Lateral Sclerosis (ALS) will use a P300 based brain computer interface (BCI) keyboard to type in assistive technology devices.
- Trial name
- NCT01119001
- Testing
- P300 Brain Computer Interface Keyboard
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan
Pure Autonomic Failure, Amyotrophic Lateral Sclerosis
Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB)
Anti alfa-3 and alfa-7 ganglionic cholinergic receptors (anti-AChRs) antibodies (Abs) plasma removal by plasmapheresis (1,2) acutely improved dysautonomia symptoms in case reports with Pure Autonomic Failure (PAF) (3).
- Conditions
- Pure Autonomic Failure, Amyotrophic Lateral Sclerosis, Postural Orthostatic Tachycardia Syndrome, Anti-Cholinergic Receptors Antibodies
- Trial name
- DISAUT-AB (NCT04875949)
- Testing
- Immunoabsorption/plasmapheresis procedure
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Istituto Clinico Humanitas
Amyotrophic Lateral Sclerosis
A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)
The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in participants with ALS.
- Trial name
- NCT06215755
- Testing
- VRG50635
- Where
- 7 sites in Belgium, Canada and 2 more
- Volunteers
- 54 people
- Sponsor
- Verge Genomics
Amyotrophic Lateral Sclerosis (ALS)
Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis
Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). Over the last years, various interventional studies targeting the energy deficit in ALS yielded promising results; however,it is still…
- Trial name
- PEGASUS (NCT06877143)
- Testing
- 100% of individual calory requirement, 120% of individual calory requirement
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- University of Ulm
Amyotrophic Lateral Sclerosis
Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by progressive weakness and muscular atrophy due to the degeneration and loss of motor neurons, the nerve cells that, in the central nervous system…
- Trial name
- NCT01569958
- Testing
- transcranial direct current stimulation
- Where
- 3 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Amyotrophic Lateral Sclerosis
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
- Trial name
- Phoenix (NCT05021536)
- Testing
- AMX0035
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 664 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.
ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS) may be included on a voluntary basis. The investigators plan to include a group of approximately 30 patients with ALS.
- Trial name
- ActiALS (NCT06228001)
- Testing
- Actimyo
- Where
- 3 sites in Belgium, Egypt
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Clinical Trial of High Dose CoQ10 in ALS
The purpose of this study is to determine the efficacy and preferred dose of CoQ10 in individuals with ALS for a possible future phase III study.
- Trial name
- NCT00243932
- Testing
- coenzyme Q10
- Where
- 19 sites in United States
- Volunteers
- 185 people
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis, Brain Stem Stroke
Real World Testing of a Brain-Computer Interface
The goal of this project is to test a new AAC-BCI device comparing gel and dry electrode headgear used for communication while providing clinical care.
- Conditions
- Amyotrophic Lateral Sclerosis, Brain Stem Stroke, Cerebral Palsy, Traumatic Brain Injury
- Trial name
- NCT04026581
- Testing
- Speech generating device (SGD) evaluation including BCI access, Training and treatment
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Pittsburgh
Amyotrophic Lateral Sclerosis
Italian Validation of the Beaumont Behavioural Inventory (BBI)
Up to 50% of patients affected with amyotrophic lateral sclerosis (ALS) can show behavioral dysfunctions within the spectrum of frontotemporal degenerations (FTD) - namely, apathy, disinhibition, loss of sympathy/empathy…
- Trial name
- BBI (NCT04440644)
- Testing
- BBI
- Where
- Italy
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Development and Test of a Headset for BCI Until Obtaining an Efficient and Comfortable System That Can be Used in Daily Practice by ALS People
"Brain-computer interfaces (BCIs) are computer-based systems that acquire brain signals, analyze them, and translate them into commands that are relayed to an output device to carry out a desired action.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Spinal Cord Diseases, Alternative Communication Devices
- Trial name
- TECH-ICOPA (NCT04380649)
- Testing
- New headset prototype
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Amyotrophic Lateral Sclerosis
Creatine for the Treatment of Amyotrophic Lateral Sclerosis
Creatine is a naturally occurring chemical involved in the production of energy in muscle. Abnormalities in creatine have been linked to the progression of degenerative neuromuscular diseases such as amyotrophic lateral sclerosis…
- Trial name
- NCT00070993
- Testing
- creatine monohydrate
- Where
- 6 sites in United States
- Volunteers
- 110 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Amyotrophic Lateral Sclerosis
Biological Treatment of Amyotrophic Lateral Sclerosis
The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells infusion in the subjects with diagnosed amyotrophic lateral sclerosis.
- Trial name
- NeuStem-ALS (NCT02193893)
- Testing
- Biological: Cell-based therapeutics, Symptomatic treatment of ALS
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Pomeranian Medical University Szczecin